30

Zhejiang Sunflower Light Energy

300111 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

3.20CNY-0.16 (-4.76%)

Price History

Full chart

Market Stats

Previous Close3.36
Open3.36
Day Range3.18 – 3.38
52-Week Range2.52 – 9.96
Volume72.87M
Market Cap3.84B
P/E (TTM)0.00
Forward P/E156.25
EPS-0.01
Dividend Yield0.00%
Beta0.49
50-Day Avg3.00
200-Day Avg3.91

About

Zhejiang Sunflower Great Health Co., Ltd. engages in the research, development, production, and sales of anti-infective, cardiovascular, and digestive system drugs in China and internationally. It offers clarithromycin raw materials, an anti-infective drugs used for nasopharyngeal infection, lower respiratory tract infection, skin and soft tissue infection, acute otitis media, mycoplasma pneumonia, and urethritis and cervicitis; clarithromycin tablets; azithromycin dispersible tablets and injection for sinusitis, acute otitis media, acute bronchitis, acute exacerbation of chronic bronchitis, streptococcus pneumoniae, pneumonia, haemophilus influenzae, mycoplasma pneumoniae, urethritis, cervicitis, and skin and soft tissue infection. The company also provides roxithromycin capsules to treat pharyngitis and tonsillitis caused by Streptococcus pyogenes, sinusitis, otitis media, acute bronchitis, and acute exacerbation, as well as urethritis, cervicitis, and skin and soft tissue infection. In addition, it offers lacidipine dispersible tablets for the treatment of hypertension; and simvastatin tablets used for hyperlipidemia, coronary heart disease combined with hypercholesterolemia, and children with heterozygous familial hypercholesterolemia. Further, the company provides omeprazole sodium for injection, a digestive system drug, used as an alternative therapy for duodenal and gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome. The company was formerly known as Zhejiang Sunflower Great Health Limited Liability Company and changed its name to Zhejiang Sunflower Great Health Co., Ltd. in December 2023. Zhejiang Sunflower Great Health Co., Ltd. was founded in 2005 and is headquartered in Shaoxing, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Huaxin Shi
  • Employees303
  • HeadquartersSanjiang Road, Shaoxing, China, 312071, China
  • Websitehttps://www.sunowe.com

Leadership

  • Mr. Huaxin ShiGM & Non-Independent Director · b. 1968
  • Mr. Wei Biao PanCFO, Deputy GM & Director · b. 1970
  • Ms. Lan LiSecretary of the Board · b. 1983
  • Danlin WuAccounting Supervisor
  • Mr. Jiangang SunDeputy General Manager

Financials

Income Statement

Currency: CNY2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue337.50M1.09B1.02B2.33B1.94B1.23B1.12B1.64B1.82B1.60B1.53B900.22M836.61M286.96M297.29M335.86M338.42M330.37M271.53M
Growth (%)-+221.76%-6.38%+129.02%-16.74%-36.76%-8.41%+46.39%+10.97%-12.14%-4.54%-41.16%-7.07%-65.70%+3.60%+12.97%+0.76%-2.38%-17.81%
Cost of Revenue297.30M903.16M788.89M1.82B1.64B1.12B884.45M1.36B1.43B1.27B1.35B892.28M695.10M184.63M188.39M239.68M254.82M256.14M214.75M
Gross Profit39.43M182.79M227.83M504.24M295.04M110.09M238.47M282.87M390.13M335.06M179.01M7.94M141.51M102.32M108.90M96.17M83.60M74.23M56.79M
Gross Margin11.68%16.83%22.41%21.65%15.22%8.98%21.24%17.21%21.39%20.90%11.70%0.88%16.92%35.66%36.63%28.64%24.70%22.47%20.91%
Operating Expense10.71M39.51M80.95M139.19M234.06M287.78M208.29M249.83M291.50M252.07M175.31M728.00M213.93M28.56M54.40M90.26M57.58M61.87M62.77M
Operating Income28.73M143.28M146.88M365.05M60.98M-177.69M30.18M33.03M98.63M82.98M3.70M-720.06M-72.42M73.76M54.49M5.91M26.02M12.35M-5.99M
Operating Margin8.51%13.19%14.45%15.68%3.15%-14.49%2.69%2.01%5.41%5.18%0.24%-79.99%-8.66%25.71%18.33%1.76%7.69%3.74%-2.20%
EBITDA35.80M171.22M173.79M377.23M166.02M-146.15M256.39M282.30M341.60M265.84M213.77M-903.91M4.28M92.83M88.69M21.16M47.28M31.31M10.00M
EBITDA Margin10.61%15.77%17.09%16.20%8.56%-11.92%22.83%17.17%18.73%16.59%13.97%-100.41%0.51%32.35%29.83%6.30%13.97%9.48%3.68%
Net Income10.89M74.93M103.34M251.31M34.84M-357.23M40.61M37.47M87.63M30.64M23.70M-1.12B-114.93M55.87M53.42M-1.14M21.75M7.83M-4.38M
Net Income Margin3.23%6.90%10.16%10.79%1.80%-29.14%3.62%2.28%4.80%1.91%1.55%-124.94%-13.74%19.47%17.97%-0.34%6.43%2.37%-1.61%
R&D----27.60M10.01M38.07M44.76M51.22M58.17M41.28M20.83M25.98M11.34M12.27M14.19M19.11M22.01M10.83M
R&D as % of Total Revenue----1.42%0.82%3.39%2.72%2.81%3.63%2.70%2.31%3.11%3.95%4.13%4.23%5.65%6.66%3.99%
Interest Expense19.86M67.72M51.73M52.48M66.84M99.34M92.30M96.41M76.99M53.98M47.81M40.31M26.75M2.94M279.03K887.20K5.34M1.97M9.16K
Interest Expense % of Total Revenue5.88%6.24%5.09%2.25%3.45%8.10%8.22%5.86%4.22%3.37%3.12%4.48%3.20%1.03%0.09%0.26%1.58%0.60%0.00%

Balance Sheet

Currency: CNY2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets555.16M1.60B1.92B2.81B3.55B3.04B2.87B3.15B3.08B2.80B2.70B1.46B694.03M564.44M631.63M616.25M1.24B999.12M984.18M
Total Liabilities451.84M1.19B1.30B1.15B2.06B1.91B1.71B1.95B1.81B1.50B1.38B1.28B522.28M293.39M221.38M201.41M432.52M176.14M165.02M
Total Equity103.31M409.97M616.58M1.66B1.49B1.13B1.16B1.21B1.27B1.30B1.31B197.59M50.35M150.17M286.90M285.79M678.33M686.24M682.03M
Cash39.59M378.44M375.47M578.02M334.50M476.90M408.10M214.21M184.18M218.49M167.61M182.17M146.69M225.64M206.09M233.19M879.15M567.37M504.87M
Total Debt386.48M809.64M1.04B924.32M1.31B1.31B1.09B1.12B780.51M676.87M739.56M518.08M113.68M1.98M932.92K33.10M46.60M4.86M-
Net Debt346.90M431.19M660.78M346.30M977.22M830.67M681.45M903.36M596.33M458.37M571.96M335.92M-33.01M-147.58M-205.16M-200.09M-831.64M-562.51M-

Cash Flow

Currency: CNY2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-123.82M-131.96M82.39M237.02M115.72M404.72M69.82M113.60M226.22M365.14M205.46M64.58M58.50M53.31M99.27M24.16M2.87M31.44M4.20M
Investing Cash Flow-69.14M-431.74M-201.77M-687.00M-593.34M-151.08M-39.30M-173.09M30.36M-33.05M-68.69M301.91M260.23M173.24M-13.33M-37.39M-13.25M-61.33M-
Financing Cash Flow204.47M681.97M169.72M743.82M147.14M-105.99M-33.01M-156.32M-202.27M-248.73M-239.08M-291.10M-449.66M-189.04M-13.32M28.45M634.50M-270.62M-
Capital Expenditure69.14M201.95M347.19M504.43M756.59M249.20M177.96M153.14M39.18M44.19M39.26M5.10M20.70M22.36M16.89M42.15M10.30M12.89M9.76M
Free Cash Flow-192.96M-333.91M-264.80M-267.41M-640.88M155.52M-108.14M-39.53M187.04M320.95M166.20M59.48M37.80M30.95M82.38M-17.99M-7.43M18.55M-5.56M
Dividends Paid18.61M38.21M116.56M53.08M272.82M89.29M87.39M80.59M78.49M63.50M40.83M31.39M20.00M17.56M60.34K187.00K1.66M1.09M8.31K
FCF to OCF155.84%253.04%-321.38%-112.82%-553.84%38.43%-154.89%-34.80%82.68%87.90%80.89%92.11%64.62%58.06%82.98%-74.47%-258.75%59.00%-132.44%
Dividend Paid to FCF-9.64%-11.44%-44.02%-19.85%-42.57%57.42%-80.82%-203.85%41.96%19.78%24.56%52.76%52.91%56.74%0.07%-1.04%-22.33%5.89%-0.15%

Earnings

Report DateSep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Aug 19, 2014Oct 26, 2014Feb 28, 2015Apr 26, 2015Aug 25, 2015Oct 26, 2015Feb 27, 2016Apr 25, 2016Aug 27, 2016Oct 28, 2016Feb 28, 2017Apr 26, 2017Aug 28, 2017Oct 29, 2017Dec 31, 2017Apr 27, 2018Aug 29, 2018Oct 29, 2018Dec 31, 2018Apr 25, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Apr 28, 2020Aug 28, 2020Oct 29, 2020Dec 31, 2020Apr 29, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Feb 19, 2024May 14, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024May 14, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate----------------------------------------------------------------
EPS Actual0.080.090.060.06-0.03-0.060.01-0.160.03-0.200.010.020.000.01-0.02-0.00-0.020.07-0.030.030.020.050.020.03-0.00-0.02-0.020.030.000.01-0.03-0.14-0.06-0.79-0.010.01-0.00-0.100.010.010.000.030.01-0.000.000.05-0.01-0.00-0.000.01-0.010.000.03-0.000.000.000.000.00-0.000.000.00-0.00-0.00-0.01
Surprise----------------------------------------------------------------
Timing---------------After-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hours-Pre-marketAfter-hoursPre-market-Pre-market------------------After-hoursAfter-hours---After-hours-----

Key Statistics & Ratios

Market Cap3.84B
Enterprise Value3.34B
Trailing P/E0.00
Forward P/E156.25
Price / Sales16.28
Price / Book5.75
EPS-0.01
Book Value0.52
Revenue (TTM)235.69M
Gross Profit (TTM)49.90M
EBITDA1.39M
Profit Margin-7.61%
Operating Margin1.15%
Return on Equity-2.10%
Return on Assets-0.73%
Shares Outstanding1.29B
Shares Float894.26M
Beta0.49
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20111×
0.18Jun 3, 2011

Stock Splits

  • Sep 4, 201322:10